TNF-alpha and Follicular Inflammation in Hidradenitis Suppurativa
Chronic TNF-alpha signaling drives painful nodules and abscesses in HS.
- ~1%: Prevalence (placeholder population estimate)
- Post-puberty: Onset (placeholder typical age)
- TNF-α: Key cytokine (placeholder driver)
- Axilla/groin: Sites (placeholder distribution)
Inflammatory cascade in HS lesions
Placeholder: follicular occlusion triggers TNF-alpha-driven immune activation.
Loading Dose Induction with Adalimumab
An initial high-dose regimen rapidly reduces circulating free TNF-alpha.
- 160mg: Loading dose (placeholder week 0)
- 80mg: Second dose (placeholder week 2)
- Subcutaneous: Route (placeholder injection)
- ~2-4wk: Onset of effect (placeholder timeline)
Induction dosing rationale
Placeholder: front-loaded dosing achieves therapeutic drug levels quickly.
How Adalimumab Neutralizes TNF-alpha
The monoclonal antibody binds soluble and membrane TNF-alpha directly.
- TNF-α: Target (placeholder cytokine)
- IgG1 mAb: Antibody type (placeholder isotype)
- High affinity: Binding (placeholder Kd)
- Blocks signaling: Effect (placeholder outcome)
Antibody-cytokine neutralization
Placeholder: bound TNF-alpha cannot engage its receptors on target cells.
Long-Term Maintenance Dosing Schedule
Weekly subcutaneous injections sustain blockade and prevent flares.
- 40mg: Maintenance dose (placeholder weekly)
- Weekly: Frequency (placeholder interval)
- Long-term: Duration (placeholder ongoing)
- Periodic labs: Monitoring (placeholder safety)
Sustaining therapeutic levels
Placeholder: consistent dosing avoids trough-related symptom breakthrough.
HiSCR — Hidradenitis Suppurativa Clinical Response
HiSCR tracks abscess and nodule reduction to gauge treatment success.
- ≥50% AN: HiSCR definition (placeholder reduction)
- Week 12: Assessment week (placeholder checkpoint)
- Reassess: Non-response action (placeholder pathway)
- Continue: Responder action (placeholder pathway)
Interpreting HiSCR outcomes
Placeholder: response status guides continuation or therapy switch decisions.
Placeholder: sustained HiSCR response supports long-term continuation.